Sign in

Mike Thompson, MD, PhD, FASCO

@mtmdphd.bsky.social
1.4K followers 146 following 229 posts

Views my own. VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: coi.asco.org/share/RBB-TT6R/Michael

PostsRepliesMedia
Reposted by Mike Thompson, MD, PhD, FASCO
Daniel Stover, MD, FASCO @stoverlab.bsky.social · 30/05/2025
Is liquid biopsy useful in bone-only metastatic #breastcancer? Surprise! ✅Pts w bone-only disease are just as likely to have detectable ctDNA ✅ctDNA tumor fraction remains prognostic in bone-only setting link.springer.com/article/10.1... @osucccjames.bsky.social
link.springer.com
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study - Breast Cancer Research and Treatment
Purpose Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequ...
171
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 04/12/2025
Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/3/25 v3 cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren @MyelomaTeacher @VincentRK #ASH25VR
040
Reposted by Mike Thompson, MD, PhD, FASCO
Chan Cheah @chancheah.bsky.social · 23/10/2025
Pleased to share EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/... #lymSM @hemasphere-journal.bsky.social
onlinelibrary.wiley.com
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
Mantle cell lymphoma (MCL) is a relatively rare B-cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse beha...
121
Reposted by Mike Thompson, MD, PhD, FASCO
Journal of Patient-Centered Research & Reviews @realjpcrr.bsky.social · 01/10/2025
NOW PUBLISHED!! JPCRR Vol. 12, Issue 4: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
133
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 30/09/2025
Look up NCI and NCORP
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 26/09/2025
Increasing access = increasing cost to increase sites, staff, etc. That is not the mode the government is currently in. Look into NCCCP and NCORP NCI programs for more background
120
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/09/2025
Many publications on this. Short answer is 1) Improve access. 2) Remove I/E criteria that are not necessary. In the US ~85% of cancer patients are treated in the community setting. #ClinicalTrials
130
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/09/2025
Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm
150
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 22/08/2025
1) The demographics of MM are usually elderly. 2) Patients are treated by oncologists who monitor side effects -- on or off a study.
110
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/08/2025
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
030
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/08/2025
Yes. Len and Dara-len are commonly used in MM therapy and tolerated
110
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 28/07/2025
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
151
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 21/07/2025
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
030
Reposted by Mike Thompson, MD, PhD, FASCO
Journal of Patient-Centered Research & Reviews @realjpcrr.bsky.social · 16/07/2025
NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
143
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/07/2025
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
041
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 13/06/2025
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine
ow.ly
Evaluation and comparison of two commercially available targeted next- | OTT
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making Glen J Weiss,1 Brandi R Hoff,1 Robert P Whitehead,1 Ashish Sang...
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 13/06/2025
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 04/06/2025
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine
lungcancerjournal.info
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer
DDR genes play a key role in detecting and repairing DNA damage and are crucial for maintaining the integrity of the genome [1]. Alterations in DDR genes are associated with genomic instability and in...
041
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 04/06/2025
Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
031
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 31/05/2025
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher
151
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 30/05/2025
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd - Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
030
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm
ow.ly
ASCO Publications
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
030
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508 meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505 meetings.asco.org/abstracts-pr... #mmsm #caxtx
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
030
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504 meetings.asco.org/abstracts-pr... #mmsm
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514 meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
020
Reposted by Mike Thompson, MD, PhD, FASCO
Cris Bergerot, PhD @crisbergerot.bsky.social · 23/05/2025
🔥 Just dropped: 6,000+ reasons to get excited for #ASCO25! From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social 🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...
0169
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544 meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041 meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants - @polanimd et al. #ASCO25 Abst 3572 meetings.asco.org/abstracts-pr... @TempusAI #crcsm #PrecisionMedicine
031
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
Cohort builder in Tempus Lens: Querying a large oncology database with generative AI - West et al. @tempusAI #ASCO25 Abstract e13589 meetings.asco.org/abstracts-pr... #hemonc
000
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025
ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC) - Lee et al. @UCLAHealth @TempusAI #ASCO25 Abst 8060 meetings.asco.org/abstracts-pr... #lcsm #ImmunoOnc #PrecisionMedicine
053
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 22/05/2025
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 22/05/2025
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology ow.ly/RSt450E2I9U #CCC19 #COVID19nCancer
ow.ly
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2...
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) - www.promisestudy.org @PromiseStudy #NCT03689595 #mmsm #wmsm #precisionprevention US adults, age 40-75, qualify for a free screening: 1. African Americans and/or 2. 1st degree relative w/ MM, MGUS, SMM, WM
promisestudy.org
Home | United States | PROMISE Study: Researching Multiple Myeloma
See if you qualify for a study screening to detect early indicators of blood cancer known as multiple myeloma. Visit The Promise Study now, part of Dana-Farber Cancer Institute. We're seeking voluntee...
011
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025
Germline predisposition in multiple myeloma [Dec 17, 2024] Rodrigues et al. iScience www.sciencedirect.com/science/arti... #mmsm #geneticcounselors 954 unrelated individuals w/ MM & 82 MM families
051
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025
Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic [Jan 23, 2025] @Erman_Akkus et al. CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #mmsm #geneticcounselors
clinical-lymphoma-myeloma-leukemia.com
Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic
Familial multiple myeloma (MM) is a relatively rare entity. Data on epidemiology, underlying germline genetic predisposition, and clinical features of familial MM continue to expand, especially in rec...
021
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR ow.ly/wC8F50IgpjR #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm
001
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 19/05/2025
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation [Sep 19, 2024] @KLChohan et al. @BloodJournal ashpublications.org/blood/articl... #lymphoidneoplasia #wmsm
021
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
021
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
011
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 17/05/2025
Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction [May 26, 2019] @kaushalpar et al. @AMansfieldMD #ASCO19 Abstract 2621 ascopubs.org/doi/abs/10.1... #PrecisionMedicine #ImmunoOnc #geneticcounselors @MayoCancerCare @TempusLabs
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025
A #mmsm classic -> Vincent Rajkumar (@VincentRK): from Madras to Minnesota for myeloma - @TheLancet ow.ly/ElUQk @eaonc
ow.ly
Vincent Rajkumar: from Madras to Minnesota for myeloma
Challenging assumptions seems to be in the blood of Vincent Rajkumar. Take his taste in music. Cerebral, temperate, and mild-mannered are the adjectives that spring immediately to mind as he talks fon...
020
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025
Robert A. Kyle, MD: Lessons From a Legend [Mar 2019] via @VincentRK @MayoProceedings PDF: ow.ly/PQ6G30nT8OQ #mmsm @RobertK68033234
ow.ly
010
Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025
Program Genealogies: Myeloma at Mayo [Jun 11, 2015] - @VincentRK & @RobertK68033234 from @MayoMyeloma ow.ly/OOi38 #mmsm
ow.ly
010